

MINORITY SHAREHOLDERS WATCH GROUP
BADAN PENGAWAS PEMEGANG SAHAM MINORITI BERHAD
(Incorporated in Malaysia – Company No. 524989-M)

New Straits Times, Business Times – Monday, February 18th, 2019(A)

MSWG AGM/EGM WEEKLY WATCH

FEBRUARY 18-22, 2019

For this week, the following are the AGMs/EGMs of companies which are in the Minority

Shareholders Watch Group's (MSWG) watch list.

The summary of points of interest is highlighted here, while the details of the questions to the companies can be obtained via MSWG's website at www.mswg.org.my

The AGMs/EGMs for the week:

Date & Time	Company	Venue
19.02.19 (Tue) 11.00 am	Kuala Lumpur Kepong Bhd (AGM)	WEIL Hotel, 292 Jalan Sultan Idris Shah, Ipoh, Perak
19.02.19 (Tue) 02.30 pm	Batu Kawan Bhd (AGM)	WEIL Hotel, 292 Jalan Sultan Idris Shah, Ipoh, Perak
20.02.19 (Wed) 10.00 am	CCM Duopharma Biotech Bhd (EGM)	Setia City Convention Centre, Setia Alam, Seksyen U13, Shah Alam

One of the points of interest to be raised:

Kuala Lumpur Kepong Bhd (AGM)

As highlighted on page 146 of the Annual Report, it has never been the Group's policy to carry out regular revaluation of its property, plant and equipment. However, certain freehold land, leasehold land and buildings were revalued by the Directors between 1966 and 1991.

Given that there has been no revaluation on the land and the buildings for a long period of time, the current value of these properties may be significantly different from the carrying amount. Will the Board consider engaging an independent valuer to revalue these land and buildings?

Batu Kawan Bhd (AGM)

A further impairment loss of RM21.625 million (FY2017: RM30.94 million) in respect of a specialised oleochemical plant was charged to other operating expenses in FY2018 (Note 12 to the Financial Statements on page 102 of the Annual Report).

The reply to our letter dated 7 February 2018 states that the technology related issues was one of the factors that had triggered the impairment loss provision in FY2017 and that these issues have largely been addressed and product sales had since improved.

- (a) Given that the product sales had improved, what then are the factors that triggered further impairment in FY2018?
- (b) Does the Board anticipate any further impairment in respect of the oleochemical plant in FY2019?